Two cases of uveitis caused by TNF-α inhibitor recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein for injection / etanercept for injection

doi:10.19803/j.1672-8629.20230281

Abstract

Abstract: Objective To investigate the correlations between TNF-α inhibitor and uveitis and to analyze the clinical features of TNF-α inhibitor-induced uveitis. Methods The clinical data of 2 patients with uveitis treated with the recombinant human tumor necrosis factor-alpha receptor II: IgG Fc fusion protein / ETANERCEPT for injection in our hospital between July 2021 and February 2023 was retrospectively analyzed, and the related literature was reviewed. Results Two female patients were collected. The onset of uveitis occurred at 2 and 6 weeks after medication, respectively, with one case of anterior uveitis and one case of anterior and intermediate uveitis. The conditions of both patients improved after symptomatic treatment. Literature review revealed that TNF-α inhibitors that caused uveitis included infliximab, adalimumab, and ETANERCEPT, which were mostly used for the treatment of rheumatoid arthritis, tumor, ankylosing spondylitis, and uveitis. The patients ranged from 5 to 77 in age, and the duration of onset ranged from 1 week to 4 years after medication. The vast majority of patients with TNF-α inhibitors-induced uveitis could recover their vision after systematic treatment and cessation of immunosuppressive agents. Conclusion The occurrence of uveitis is closely related to the use of TNF-α inhibitors, and the type of uveitis is predominantly anterior uveitis with a high chance of recurrence. Most patients have a favorable visual prognosis after prompt diagnosis and treatment.

Key words: TNF-α inhibitor, recombinant human tumor necrosis factor-alpha receptor II: IgG Fc fusion protein / ETANERCEPT for injection, uveitis, side effects, infliximab, adalimumab, vision

CLC Number:

R988.1

SUN Wu, CHEN Shuiling, ZHOU Wanyu, SHI Hang, LIU Lu, HE Yan, FU Wentao, CHU Liqun. Two cases of uveitis caused by TNF-α inhibitor recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein for injection / etanercept for injection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 457-460.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230281

https://www.zgywjj.com/EN/Y2024/V21/I4/457

References

[1] LEONE GM, MANGANO K, PETRALIA MC, et al.Past, present and (foreseeable) future of biological anti-TNF alpha therapy[J]. J Clin Med, 2023, 12(4): 1630.
[2] SAMALIA P, SIMS J, NIEDERER R.Drug-induced ocular inflammation[J]. N Z Med J, 2020, 133(1527): 83-94.
[3] ABDALLA ELSAYED MEA, KOZAK I.Pharmacologically induced uveitis[J]. Surv Ophthalmol, 2021, 66(5): 781-801.
[4] LIM LL, FRAUNFELDER FW, ROSENBAUM JT.Do tumor necrosis factor inhibitors cause uveitis? A registry-based study[J]. Arthritis Rheum, 2007, 56(10): 3248-3252.
[5] WENDLING D, PACCOU J, BERTHELOT JM, et al.New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases[J]. Semin Arthritis Rheum, 2011, 41(3): 503-510.
[6] MOORTHY RS, MOORTHY MS, JR CUNNINGHAM ET.Drug-induced uveitis[J]. Curr Opin Ophthalmol, 2018, 29(6): 588-603.
[7] CHOI EY, LEE M, LEE CS.Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients[J]. Clin Exp Rheumatol, 2020, 38(6): 1132-1137.
[8] ABDALLA ELSAYED MEA, KOZAK I.Pharmacologically induced uveitis[J]. Surv Ophthalmol. 2021, 66(5): 781-801.
[9] EL-SHABRAWI Y, WEGSCHEIDER BJ, WEGER M, et al.Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations[J]. Ophthalmology, 2006, 113(4): 695-700.
[10] RAMOS-CASALS M, PEREZ-ALVAREZ R, DIAZ-LAGARES C, et al.Autoimmune diseases induced by biological agents: A double-edged sword?[J]. Autoimmun Rev, 2010, 9: 188-93.
[11] VERGOUWEN DPC, ROTHOVA A, BERGE JCT, et al.Current insights in the pathogenesis of scleritis[J]. Exp Eye Res, 2020, 197: 108078.
[12] GAUJOUX-VIALA C, GIAMPIETRO C, GAUJOUX T, et al.Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease[J]. J Rheumatol, 2012, 39(2): 233-239.
[13] SMITH JR, HART PH, COSTER DJ, et al.Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis[J]. Invest Ophthalmol Vis Sci, 1998, 39(3): 658-661.
[14] DAVIES R, DE COCK D, KEARSLEY-FLEET L, et al.The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data[J]. Rheumatology (Oxford), 2020, 59(6): 1391-1397.
[15] RAWAT BPS, JAGANNATHA A, LIU F, et al.Inferring ADR causality by predicting the Naranjo Score from Clinical Notes[J]. AMIA Annu Symp Proc, 2021, 2020: 1041-1049.
[16] TANTIKUL C, DHANA N, JONGJAREARNPRASERT K, et al.The utility of the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children[J]. Asian Pac J Allergy Immunol, 2008, 26(2-3): 77-82.
[17] SHUKLA AK, JHAJ R, MISRA S, et al.Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions[J]. J Family Med Prim Care, 2021, 10(9): 3303-3308.
[18] SIVAGOUROUNADIN K, RAJENDRAN P, SELVARAJAN S, et al.Agreement among different scales for causality assessment in drug-induced stevens-johnson syndrome and toxic epidermal necrolysis[J]. Curr Drug Saf, 2022, 17(1): 40-46.